Medexus joined as a new agent in the National Bank of Canada

Announcement

Medexus Pharmaceuticals has joined hands with the National Bank of Canada as an administrative agent under the new senior secured credit agreement. This new credit agreement will deliver US$21.0 million term loan facility and a revolving loan facility worth US$5.0. The term loan facility is an advantage with an additional US$10.0 million late draw feature.

The feature is planned to finance effectively the future acquisitions and licensing amounts, and to a US$15.0 million unmentioned accordion feature. From 17th November 2029, these new facilities will be counted as mature and confirmed after four years from the date of the credit agreement.

Chief Financial Officer of Medexus, Brendon Buschman, said, “We are grateful to declare this non-dilutive and long-standing financing, which elaborates our reach to competitive and capital terms. Medexus has described an enhanced and advanced financial strategy and growth as its operating profile since the GRAFAPEX™ for injection in February 2025 entered as a positive change and excellence. We are thankful that our new partners at National Bank of Canada have realised our potential and power in business, involving a full-fledged focus beyond the GRAFAPEX™ launch.”

Medexus’s capitalisation strategy

Medexus’s smart capital allocation move is purpose-built as the company plans to start an NCIB or normal course issuer bid for its common shares, entitled to the clearance of the Toronto Stock Exchange (TSX). On approval from the TSX, Medexus will then get permission to buy for cancellation via facilities provided by the TSX or any other availed means of around 10% of the public float.

Respectively to the calculation according to the TSX rules, Medexus’s outstanding and issued common shares in the 12 months following any of the TSX approvals at predominant market prices or any other means permitted in accordance with the TSX rules.

The original number of common shares that Medexus may select to buy under the NCIB and the durability of any such buy-out will be determined by Medexus. These shares will be entitled to the valid and compulsory limitations and terms of the NCIB involving any automatic-based share purchase plans. There’s no assurance of how many common shares Medexus can buy under the NCIB.

Buschman added, “NCIB is an essential and valuable addition to our capital smart allocation strategy. If approved by the TSX, our purchases will be beneficial to both investors and the company.”